Graft-Versus-Host Disease Clinical Trials

6 recruiting

Frequently Asked Questions

Common questions about Graft-Versus-Host Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

Graft-Versus-Host DiseaseGraft-versus-leukemiaDonor Apheresis
National Heart, Lung, and Blood Institute (NHLBI)500 enrolled1 locationNCT00001529
Recruiting
Phase 1

Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia

Graft-Versus-Host DiseaseXerostomiaSjogren's Disease
University of Wisconsin, Madison36 enrolled1 locationNCT06392711
Recruiting
Phase 2

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

T-cell LymphomaT-cell Prolymphocytic LeukemiaLymphoma, T-Cell+5 more
Jonathan Brammer44 enrolled1 locationNCT07356245
Recruiting

Psychiatric Status and Symptom Severity in Graft-versus-Host Disease (GvHD).

Quality of LifeCognitive ImpairmentsGvHD+3 more
Medical University of Gdansk200 enrolled1 locationNCT07314892
Recruiting
Phase 2

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome+3 more
City of Hope Medical Center35 enrolled1 locationNCT06815003
Recruiting

SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography

Oral CancerOral Squamous Cell CarcinomaActinic Keratoses+9 more
University of Palermo200 enrolled1 locationNCT06321003
Recruiting
Not Applicable

Safety and Efficacy of Fecal Microbiota Transplantation

AlopeciaDiabetes MellitusObesity+24 more
Chinese University of Hong Kong450 enrolled1 locationNCT04014413